Tools
Stock profile

CVS HEALTH Corp (CVS)

CVS · Latest close $81.35 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$81.35
As of Nov 18, 2026
Tracked funds holding
13 of 149
2026 Q2 13F filings
Opened / added
2 / 2
vs previous quarter
Trimmed / exited
10
vs previous quarter

CVS HEALTH Corp (CVS) is held by 13 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 2 funds opening new positions, 2 funds adding, and 10 funds trimming or exiting versus the previous quarter. Insiders were net buyers over the last 90 days ($2.0M bought vs $0 sold). Latest close $81.35 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: Nov 6, 2026 · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Insiders · 90d
net $2.0M
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Fairfax Financial Holdings · Davis Advisors · Patient Capital Management — 13 tracked funds hold CVS. See all holders.

Insider and Congress activity

Insiders bought on the open market (1 purchase, $2.0M) vs 0 sales ($0). Latest buy: Nov 6, 2026. Insider trading

Often held alongside

CONSTELLATION BRANDS, INC. (STZ) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · APA Corp (APA) · FIFTH THIRD BANCORP (FITB) · ISHARES RUSSELL 1000 ETF (IWB) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Fairfax Financial Holdings10.63%2,712,000HELD Q3 filed Nov 16
Davis Advisors5.27%11,865,916TRIMMED (-3.1%) Q3 filed Nov 10
Patient Capital Management4.19%1,235,505TRIMMED (-9.0%) Q3 filed Nov 12
Hillman Capital Management4.15%55,475TRIMMED (-17.8%) Q3 filed Nov 16
Pzena Investment Management3.57%11,769,536TRIMMED (-14.5%) Q3 filed Oct 30
Dodge & Cox Funds2.71%50,012,765TRIMMED (-3.4%) Q3 filed Nov 13
GQG Partners1.53%7,955,411ADDED (+25136.8%) Q3 filed Nov 13
Viking Global Investors1.08%3,663,361NEW Q3 filed Nov 16
Ariel Investments0.75%730,110ADDED (+4.0%) Q3 filed Nov 13
Oakmark Funds0.05%335,817TRIMMED (-32.0%) Q3 filed Nov 16

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -18.1% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

110.6041.112024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

172016Q4: 17 funds2017Q1: 16 funds2017Q2: 16 funds2016Q42017Q2

Tracked funds holding this stock, by quarter (2016Q4–2017Q2, 3 quarters). Source: quarterly BEST lists from 13F filings — tracked funds only, not all filers. A stock appears here only if it ever made a quarterly BEST list.

All institutions · Form 13F

Institutions holding2,075 of 8,857 filers
Long-only filers among them2,062
Change vs 2026 Q1+225 net · 1,631 entered · 1,406 exited
Shares reported, all filers1,130,618,041
Reported value, all filers$115.0B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNYSE
IndustryRetail-Drug Stores and Proprietary Stores (SIC 5912)
Revenue · FY2025$402.1B
Net income · FY2025$1.8B
Total assets · FY2025$253.5B
Shares outstanding1,278,970,369
Market cap (at latest close)$104.0B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Jul 29, 2026.

Short interest

Shares short · Oct 15, 202616,193,404
Share of shares outstanding1.27%
Days to cover1.57

Shares short at recent settlements — Jul 31, 2026: 18.7M · Aug 14, 2026: 16.8M · Aug 31, 2026: 18.1M · Sep 15, 2026: 16.1M · Sep 30, 2026: 16.5M · Oct 15, 2026: 16.2M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Jul 29, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Jul 29, 2026.

Insider trading · Form 4

1 insider bought on the open market in the last 90 days (1 purchase, $2.0M), against 0 sales by 0 insiders ($0). Latest buy: Nov 6, 2026.

$1M+ open-market buy

Source: SEC Form 4 filings. Open-market transactions only.

Latest open-market buyTransaction pricePrice change since disclosure
Shah Prem S · 23,855 shares on Nov 6, 2026 · filed Nov 6, 2026$83.89+0.7% (close Nov 9, 2026 → Nov 17, 2026)

Reference close is the first trading day after the filing (Nov 9, 2026). The transaction price is what the insider paid; the price change is on closing prices (dividends excluded).

Recent open-market trades

DateInsiderRoleBuy / SellSharesPriceValueSource
Nov 6, 2026Shah Prem SEVP and Group PresidentBuy23,855$83.89$2.0MSEC filing

Most recent open-market transactions in the same 90-day window, most recent first. Source: SEC Form 4 filings.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
May 22, 2026AGUIRRE FERNANDODirector2,263$214.3KMay 20, 2026SEC filing
May 21, 2026FARAH ROGER NDirector2,817$263.9KMay 21, 2026SEC filing
May 8, 2026TILAK MANDADIOfficer69,551$6.2MMay 8, 2026SEC filing
Aug 19, 2025Finucane Anne A.Director7,500$532.3KAug 20, 2025SEC filing
Mar 5, 2025Clark James DavidOfficer7,513$498.5KMar 5, 2025SEC filing
Feb 16, 2024PREM S SHAHOfficer29,473$2.3MFeb 16, 2024SEC filing
Aug 3, 2023Clark James DavidOfficer25,759$1.9MAug 3, 2023SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 13, 2026Dodge & CoxSC 13G/A50,012,7653.9%Jun 30, 2026SEC filing
Apr 29, 2026Vanguard Capital ManagementSC 13G95,598,5287.5%Mar 31, 2026SEC filing
Mar 26, 2026The Vanguard GroupSC 13G/A00.0%Mar 13, 2026SEC filing
Jul 16, 2025BlackRock, Inc.SC 13G/A105,292,5888.3%Jun 30, 2025SEC filing
May 13, 2025Capital World InvestorsSC 13G68,785,9905.5%Mar 31, 2025SEC filing
Apr 17, 2025BlackRock, Inc.SC 13G/A89,218,2687.1%Mar 31, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Retail-Drug Stores and Proprietary Stores (SIC 5912). No standing committee maps to this industry under the site’s jurisdiction rule — see Methodology.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: no Lobbying Disclosure Act filings matched for this ticker (1999–2026).

Federal contracts: $597.4M in obligated amounts, fiscal years 2021–2026.

Fiscal yearObligated amount
FY2021$78.5M
FY2022$355.7M
FY2023$130.1M
FY2024$20.2M
FY2025$7.1M
FY2026$5.8M

Largest awards collected

Award IDAgencyAmountStart
75A50121C00090Department of Health and Human Services$498.2KSep 30, 2021
36C25222P0236Department of Veterans Affairs$45.1KDec 22, 2021
15B30224P00000151Department of Justice$26.6KFeb 12, 2024
36C24122P0929Department of Veterans Affairs$26.2KAug 31, 2022
68HERC22P0026Environmental Protection Agency$20.0KFeb 15, 2022

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Insiders

· Large Insider Buys — Last 90 days: a single buy trade of $1M or more

· Insider Net Buying — Last 90 days: more insider buy transactions than sell transactions

Financial Screens

· Growth — Revenue up every year for 5 straight years

· Dividend Growth — Dividends raised for more than 10 years

· Cash Flow (FCF) — Positive free cash flow in each of the last 3 years, with an FCF yield of at least 5%

· Earnings Quality (Cash Conversion) — Profits that actually come back as cash

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Growth — Latest revenue: $402.1B · 5-yr revenue CAGR: 8.4% · Straight growth years: 15

· Dividend Growth — Dividend per share: 2.66 · Dividend yield: 2.9% · Straight dividend years: 19 · 10-yr dividend growth: 56.5%

· Cash Flow (FCF) — Latest FCF: $7.8B · FCF yield: 6.8% · Positive FCF years: 3

· Earnings Quality (Cash Conversion) — Cash conversion (3-yr avg): 3.20 · Operating cash flow: $10.6B · Net income: $1.8B

· Large Insider Buys — Buy value: $2.0M · Buy txns: 1 · Insiders buying: 1 · Latest buy: Nov 6, 2026

· Insider Net Buying — Buy txns: 1 · Sell txns: 0 · Buy value: $2.0M · Latest buy: Nov 6, 2026

· Distress Risk (Altman Z″) — Z″-Score: 0.99 · Working capital / assets: -0.06 · Retained earnings / assets: 0.24 · EBIT / assets: 0.02 · Equity / liabilities: 0.42

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Super-investor 13F BEST — appeared in 3 of the last 40 quarterly lists; latest 2017 Q2, ranked #44 of 50.

· Insider BEST — appeared in 1 of the last 20 quarterly lists; latest 2024 Q2, ranked #44 of 50.

· Politician BEST — appeared in 1 of the last 20 quarterly lists; latest 2021 Q4, ranked #16 of 50.

13F signal (2021 Q3 – 2026 Q1)EventsWin rateAvg returnSPYExcess
Heavy accumulation — 3+ tracked funds increased together1457.1%+3.3%+2.8%+0.5%
Share count tripled (3x)366.7%+3.1%+4.8%-1.7%

Measured from SEC 13F filings: entry at the close on the first trading day after each quarter’s filing deadline, exit one quarter later on the same rule, dividend-adjusted closes. Past records do not guarantee future results — see Track Record and Methodology.

Also held by the tracked funds that hold CVS — ranked by lift, the co-holding pattern described in Methodology: CONSTELLATION BRANDS, INC. (STZ) · AMERICAN INTERNATIONAL GROUP, INC. (AIG) · APA Corp (APA) · FIFTH THIRD BANCORP (FITB) · ISHARES RUSSELL 1000 ETF (IWB) · M&T BANK CORP (MTB) · UBS Group AG (UBS) · Corebridge Financial, Inc. (CRBG).

Filings audit: every filing lens on CVS HEALTH Corp (CVS), scored — GetCoattail Research.

Recent 8-K filings

FiledItemsSource
Nov 4, 20267.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing
Nov 4, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 17, 20265.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers · 7.01 Regulation FD Disclosure · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

CONSTELLATION BRANDS, INC. (STZ) · Filings audit: every filing lens on CVS HEALTH Corp (CVS), scored · Practice timing on CVS

One email a week: the week’s new filings and research. Subscribe free

← CVNA  ·  CVSA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.